Recent progress in metabolomic analysis of acute coronary syndrome: a narrative review
Authors:
- Jiaqi LiuJLJiaqi Liu
- Tingmiao LiTLTingmiao Li
- Xin QiXQXin Qi
- Chengyan HeCHChengyan He
Open Access
- 1 April 2025
- journal article
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 15 (2) , 480-499
Abstract
Background and Objective: Acute coronary syndrome (ACS) is a common cardiovascular disease in clinical practice. It is caused mainly by vulnerable plaque rupture (PR) or surface plaque erosion (PE) caused by serious thrombotic events, and eventually leads to myocardial blood supply insufficiency or necrosis. The disease has high morbidity and mortality rates. In this study, we review the literature on biomarkers of ACS metabolites and modification of disease by altering related metabolic pathways through drugs, aiming to provide clarity on potential biomarkers of disease identified to date. Methods: PubMed was used for literature review. From January 1, 2014 to December 3, 2024, English articles on clinical trials, randomized controlled trials of metabolomics studies in ACS were included. Key Content and Findings: In this review, we discuss the advantages and disadvantages of three techniques currently used for metabolomic analysis. In addition, the recent decade of metabolomic approaches to the discovery of potential diagnostic and prognostic biomarkers for ACS is reviewed. It was found that the metabolites changed in patients with ACS were mostly amino acids, lipids and carbohydrates. Tryptophan and glutamine can be used as potential diagnostic biomarkers. Mannitol and ceramide can be used as prognostic biomarkers. Drugs can improve disease by affecting changes in metabolites in the body. Conclusions: ACS studies based on metabolomics have demonstrated great potential for identifying disease-related metabolomic features in the discovery of potential biomarkers for diagnosis and prognosis and mechanisms of drug therapy.Keywords
This publication has 88 references indexed in Scilit:
- Metabolomics for laboratory diagnosticsJournal of Pharmaceutical and Biomedical Analysis, 2015
- Metabolic pathways involved in Xin-Ke-Shu protecting against myocardial infarction in rats using ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2014
- Current practice of liquid chromatography–mass spectrometry in metabolomics and metabonomicsJournal of Pharmaceutical and Biomedical Analysis, 2014
- Identification of biomarkers for unstable angina by plasma metabolomic profilingMolecular BioSystems, 2013
- Acute coronary syndrome – the present and future role of biomarkers1)Clinical Chemistry and Laboratory Medicine (CCLM), 2013
- Metabonomic Profiles Delineate the Effect of Traditional Chinese Medicine Sini Decoction on Myocardial Infarction in RatsPLOS ONE, 2012
- Prognostic Value of Biomarkers During and After Non–ST-Segment Elevation Acute Coronary SyndromeJACC, 2009
- Cardiac Metabolism in Myocardial IschemiaCurrent Pharmaceutical Design, 2008
- Troponin: the biomarker of choice for the detection of cardiac injuryCanadian Medical Association Journal, 2005
- The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysisJACC, 2001